|
BACKGROUND
Unpredicted cardiotoxicity and cardiovascular safety concerns are responsible for the termination of nearly one-third of all compounds in drug discovery pipelines. These unforeseen adverse effects add significant cost and time to therapeutic discovery and expose patients to an unneeded risk of harm.
Current in vitro and in vivo preclinical...
|
